Medicago's Plant-Based COVID-19 Vaccine Shows Positive Phase 2 ResultsMay 26, 2021
Quebec City-based Medicago and GlaxoSmithKline (GSK) have announced the positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which was tested in combination with GSK's pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing.
The results show that immunogenicity, as measured by the neutralizing antibody titer, was high at about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration. "We are very excited to see such positive results from the Phase 2 data. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses in all subjects, irrespectively of age," said Nathalie Landry, Executive Vice President of Scientific and Medical Affairs at Medicago.
The Phase 3 trial of Medicago's vaccine candidate was launched on March 16, 2021. Trial sites include subjects in Canada, the United States, the United Kingdom, and Brazil, with additional sites expected to be added in the coming weeks. The vaccine candidate has received Fast Track designation by the FDA in the United States, and Health Canada has initiated a review of Medicago's COVID-19 rolling submission under the Interim Order.
For more details, read the news release from Medicago.
You might also like:
- Plant-Based COVID-19 Vaccine Candidate Starts Phase 3 Trial
- Human Trials Begin for COVID-19 Plant-Based Technology Vaccine
- Medicago Announces Positive Results of Trials for its COVID-19 Vaccine Candidate
The Crop Biotech Update is a weekly newsletter of ISAAA, a non-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
- Medicago's Plant-Based COVID-19 Vaccine Shows Positive Phase 2 Results
News from Around the World
- GM White Maize Contributes to Food Security in South Africa
- Study Shows Plants Respond to Different Light Intensities
- Scientists Discover Ancient Melon Key in Breeding Disease-Resistant Watermelons
- Researchers Identify Genomic Regions Associated with Yield Potential and Climate Resilience in Bread Wheat
- World Vegetable Center Sends Seeds to the Svalbard Global Seed Vault
- Herbicide Tolerant GM Canola Gets Commercial Approval in Australia
- BGLS-producing Potatoes Could Lead to Broad-spectrum Protection from Pest and Diseases
- Scientists Show Correlation of Cry1Ac mRNA and Protein Abundance in Biotech Cotton Plant
- Polish Wheat's Long Grain Trait Traced to One Genetic Component
- Identified Fruit Protein Helps Control Tomato Ripening
Plant Breeding Innovations
- Rice VCS1 as Tool to Mark and Visualize Vegetative Cell of Pollen
Subscribe to CBU: